欧洲药品管理局批准的非HIV抗病毒药物研发过程中的临床前与临床研究:一篇叙述性综述
本叙述性综述提取欧洲药品管理局(EMA)自成立以来批准的非HIV系统性抗病毒药物的公共评估报告和产品特征摘要,分析21种已批准药物的临床前与临床研究。多数药物获批用于丙型肝炎(38%)和乙型肝炎(19%),其次为流感和SARS-CoV-2(14%和10%)。临床前疗效研究方法存在异质性,临床研究样本量从数百到数千例不等,许多药物需大量药物相互作用研究。
要点
- 21种EMA批准的非HIV抗病毒药物中,丙型肝炎占38%、乙型肝炎占19%、流感占14%、SARS-CoV-2占10%。
- 临床前疗效研究方法存在异质性,部分源于病毒与宿主多样性及EMA缺乏抗病毒药代动力学/药效学通用指南。
- 许多抗病毒药物有较高的细胞色素P450及其他酶相互作用潜力,导致需要大量药物相互作用研究。
核心结论
- 鉴于现有和新发病毒性疾病对有效治疗方案的持续需求,简化抗病毒药物研发流程并提供更多指南至关重要。
研究设计与样本
- 叙述性综述,数据提取自EMA发布的欧洲公共评估报告和产品特征摘要,分析自EMA成立以来批准的非HIV系统性抗病毒药物。
主要发现
- 共分析21种当前批准的非HIV抗病毒药物,其中丙型肝炎占38%、乙型肝炎占19%、流感占14%、SARS-CoV-2占10%,少数用于丁型肝炎、巨细胞病毒和痘病毒。
- 临床前疗效研究方法存在异质性,部分由病毒和宿主多样性及EMA缺乏抗病毒药代动力学和药效学通用指南解释。
- 临床研究样本量从数百到数千例患者不等。
- 许多抗病毒药物有较高的细胞色素P450及其他酶相互作用潜力,导致需要大量药物相互作用研究。
- 特殊上市授权包括对COVID-19治疗药物奈玛特韦/利托那韦的条件批准,以及对痘病毒治疗药物替考韦马特的特殊情况授权。
关键数值与推荐
- 丙型肝炎药物占38%,乙型肝炎占19%,流感占14%,SARS-CoV-2占10%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Viral diseases represent a substantial global health challenge, necessitating the urgent development of effective antiviral medications. OBJECTIVES: This review aims to present a thorough examination of systemic antiviral drugs approved by the European Medicines Agency (EMA) since its founding, excluding those targeting HIV, with a focus on preclinical and clinical studies in the drug development process. SOURCES: Data was extracted from the European Public Assessment Reports and Summary of Product Characteristics issued by the EMA. CONTENT: In total, 21 currently approved agents were analysed with a focus on preclinical and clinical studies. The majority of substances have been approved for hepatitis C (38%) and B (19%) followed by influenza and SARS-CoV-2 (14% and 10%, respectively). A smaller subset obtained approval for the indications of hepatitis D, cytomegalovirus, and pox viruses. As for preclinical studies, heterogeneity in the methods used for efficacy studies was observed, which is at least partly explained by the diverse nature of viruses and their hosts and the lack of general guidelines for antiviral pharmacokinetics and pharmacodynamics studies by the EMA. Clinical studies varied in sample sizes, ranging from a few hundred to several thousand patients. Many antiviral agents have a high potential for cytochrome P450 (CYP) and other enzyme interactions, resulting in the need for a high number of drug-drug interaction studies. Special market authorizations are available, including conditional approval for urgently required drugs such as nirmatrelvir/ritonavir for the treatment of COVID-19, and authorization under exceptional circumstances when comprehensive data cannot be provided, as seen with tecovirimat for pox viruses. IMPLICATIONS: Streamlining the drug development process of antiviral substances and providing more guidelines would be crucial given the ongoing demand for effective treatment options for existing and new viral diseases.
引用
- Pracher L, Zeitlinger M. Preclinical and clinical studies in the drug development process of European Medicines Agency-approved non-HIV antiviral agents: a narrative review. Clin Microbiol Infect. 2024. PMID: 39389465. doi:10.1016/j.cmi.2024.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。